

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 081 230 A2

12

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
07.03.2001 Bulletin 2001/10

(51) Int. Cl.⁷: **C12P 19/26**
// (C12P19/26, C12R1:185,
1:15, 1:36, 1:46, 1:85, 1:19)

(21) Application number: 00118139.5

(22) Date of filing: 29.08.2000

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 30.08.1999 JP 24267099

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicant:
KYOWA HAKKO KOGYO CO., LTD.
Chiyoda-ku, Tokyo 100-8185 (JP)

(72) Inventors:
• Koizumi, Satoshi,
Kyowa Hakko Kogyo Co., Ltd.
Machida-shi, Tokyo 194-8533 (JP)

• Tabata, Kazuhiko,
Kyowa Hakko Kogyo Co., Ltd.
Hofu-shi, Yamaguchi 747-8522 (JP)
• Endo, Tetsuo,
Kyowa Hakko Kogyo Co., Ltd.
Machida-shi, Tokyo 194-8533 (JP)
• Ozaki, Akio,
Kyowa Hakko Kogyo Co., Ltd.
Hofu-shi, Yamaguchi 747-8522 (JP)

(74) Representative:
Casalonga, Axel et al
BUREAU D.A. CASALONGA - JOSSE
Morassistrasse 8
80469 München (DE)

(54) Process for producing N-acetyl-neuraminic acid

(57) The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture, (iii) N-acetylmannosamine, and (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and recovering N-acetylneuraminic acid from the aqueous medium.

EP 1 081 230 A2

DescriptionBackground of the Invention

- 5 [0001] The present invention relates to a process for producing N-acetylneuraminic acid by using a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity.
- [0002] It is known that N-acetylneuraminic acid can be produced by extraction, decomposition or by use of enzymes. An example of a known method by extraction is extraction from a nest of sea swallows, etc. [Carbohydrate Research, **56**, 423 (1977)].
- 10 [0003] An example of a known method by decomposition is decomposition of colominic acid, which is an N-acetylneuraminic acid polymer produced by *Escherichia coli*, etc. [J. Biochem., **82**, 1425 (1977)].
- [0004] Known methods utilizing enzymes include the following: methods using N-acetylneuraminic acid aldolase, pyruvic acid and N-acetylmannosamine [J. Am. Chem. Soc., **110**, 6481 (1988); J. Am. Chem. Soc., **110**, 7159 (1988)]; a method using N-acetylneuraminic acid aldolase, pyruvic acid and N-acetylglucosamine under alkaline conditions
- 15 (U.S. Patent No. 5,665,574); methods using N-acetylneuraminic acid aldolase, N-acetylglucosamine 2-epimerase, pyruvic acid and N-acetylglucosamine [Angew. Chem. Int. Ed. Eng., **30**, 827 (1991); Carbohydrate Research, **306**, 575 (1998)]; and methods using N-acetylneuraminic acid synthetase, phosphoenolpyruvic acid and N-acetylmannosamine [Japanese Published Unexamined Patent Application No. 4961/98; Glycobiology, **7**, 697 (1997)].
- [0005] The above methods for producing N-acetylneuraminic acid require complicated operations or expensive materials such as pyruvic acid and phosphoenolpyruvic acid, and an economical method for producing N-acetylneuraminic acid has not been established yet.
- 20 [0006] So far, there has been no report describing or suggesting that N-acetylneuraminic acid can be produced by utilizing a culture of a microorganism or a treated matter thereof.
- [0007] As for the N-acetylneuraminic acid aldolase, those derived from animals and plants are known, and it is known that microorganisms belonging to the genus *Escherichia* have the activity of this enzyme. Also known is the presence of the gene encoding this enzyme, nanA, in an *Escherichia coli* strain [Nucleic Acids Res., **13**, 8843 (1985)].
- 25 [0008] N-Acetylneuraminic acid synthetase is known to be present in microorganisms belonging to the genera *Escherichia*, *Neisseria* and *Streptococcus*, etc., and it is known that an *Escherichia coli* strain has the gene encoding this enzyme, neuB [J. Bacteriol., **177**, 312 (1995)].
- 30 [0009] N-Acetylglucosamine 2-epimerase is known to be present in pigs and rats. The properties of the enzyme derived from pig have been investigated [Biochemistry, **17**, 3363 (1970)] and the gene encoding the enzyme [J. Biol. Chem., **271**, 16294 (1996)] has been obtained. So far, no microorganism having the activity of this enzyme is known.
- [0010] As to the production of pyruvic acid, a process for producing pyruvic acid by using a mutant of *Escherichia coli* is known [Biosci. Biotech. Biochem., **58**, 2164 (1994)].
- 35 [0011] As to the production of phosphoenolpyruvic acid, a process for producing phosphoenolpyruvic acid by using microorganisms of *Saccharomyces*, etc. is known (Japanese Published Unexamined Patent Application No. 197778/94).
- [0012] An object of the present invention is to provide a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. A further object of the present invention is to provide a process for producing N-acetylneuraminic acid without using expensive N-acetylmannosamine.
- 40

Summary of the Invention

- 45 [0013] The present inventors have made an intensive investigation to attain the above objects and have found that N-acetylneuraminic acid can be efficiently produced from inexpensive materials by utilizing a microorganism which is capable of producing pyruvic acid or phosphoenolpyruvic acid. The present invention has been completed based on this finding.
- [0014] The present invention relates to the following (1) - (11).

50 (1) A process for producing N-acetylneuraminic acid which comprises:

allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid aldolase activity is used in (i) above, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid synthetase activity is used in (i) above. (iii) N-acetylmannosamine, and (iv) an energy source which is necessary

55

for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and recovering N-acetylneuraminic acid from the aqueous medium.

(2) The process according to the above (1) wherein said N-acetylmannosamine is produced by allowing a culture of a microorganism having N-acetylglucosamine 2-epimerase activity or a treated matter of the culture and N-acetylglucosamine to be present in an aqueous medium to form and accumulate N-acetylmannosamine in the aqueous medium.

(3) The process according to the above (2) wherein said microorganism having N-acetylglucosamine 2-epimerase activity carries a recombinant DNA composed of a DNA fragment comprising DNA encoding N-acetylglucosamine 2-epimerase and a vector.

(4) The process according to the above (3) wherein said DNA encoding N-acetylglucosamine 2-epimerase is DNA derived from a microorganism belonging to the genus Synechocystis.

(5) The process according to the above (3) or (4) wherein said DNA encoding N-acetylglucosamine 2-epimerase is selected from the group consisting of:

(a) DNA encoding a protein having the amino acid sequence shown in SEQ ID NO: 1; and

(b) DNA having the nucleotide sequence shown in SEQ ID NO: 2.

(6) The process according to any of the above (1) - (5) wherein said microorganism having N-acetylneuraminic acid aldolase activity is a microorganism belonging to the genus Escherichia or Corynebacterium.

(7) The process according to any of the above (1) - (6) wherein said microorganism having N-acetylneuraminic acid synthetase activity is a microorganism belonging to a genus selected from the group consisting of Escherichia, Neisseria and Streptococcus.

(8) The process according to any of the above (1) - (7) wherein said microorganism capable of producing pyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.

(9) The process according to any of the above (1) - (8) wherein said microorganism capable of producing phosphoenolpyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.

(10) The process according to any of the above (6)-(9) wherein said microorganism belonging to the genus Escherichia is Escherichia coli.

(11) The process according to the above (6), (8) or (9) wherein said microorganism belonging to the genus Corynebacterium is Corynebacterium ammoniagenes, Corynebacterium glutamicum or Corynebacterium acetoacidophilum.

Brief Description of the Drawings

[0015]

Fig. 1 shows the steps for constructing plasmid pTA3 expressing N-acetylneuraminic acid aldolase.

Fig. 2 shows the steps for constructing plasmid pYP18 expressing N-acetylneuraminic acid synthetase.

Fig. 3 shows the steps for constructing plasmid pYP16 expressing N-acetylglucosamine 2-epimerase.

[Explanation of Symbols]

[0016]

Amp^r: Ampicillin resistance gene

P_L: P_L-promoter

cl857: cl857 repressor

P_{lac}: lac promoter

slr1975: N-Acetylglucosamine 2-epimerase gene

nanA: N-Acetylneuraminic acid aldolase gene

neuB: N-Acetylneuraminic acid synthetase gene

Detailed Description of the Invention

[0017] In the process of the present invention, any microorganism having N-acetylneuraminic acid aldolase activity can be used. For example, microorganisms belonging to the genus Escherichia or Corynebacterium may be used.

5 [0018] Examples of the microorganisms belonging to the genus Escherichia are those of the species Escherichia coli. Examples of the microorganisms belonging to the genus Corynebacterium are those of the species Corynebacterium ammoniagenes, Corynebacterium glutamicum and Corynebacterium acetoacidophilum.

[0019] Also useful are transformants with N-acetylneuraminic acid aldolase activity enhanced by recombinant DNA techniques. Examples of such transformants include microorganisms carrying a recombinant DNA comprising nanA gene derived from Escherichia coli [Nucleic Acids Res., 13, 8843 (1985)], specifically, Escherichia coli NM522/pTA3.

10 [0020] Any microorganism having N-acetylneuraminic acid synthetase activity can be used in the process of the present invention. For example, microorganisms belonging to the genus Escherichia, Neisseria or Streptococcus may be used.

[0021] Examples of the microorganisms belonging to the genus Escherichia are those of the species Escherichia coli.

15 [0022] Also useful are transformants with N-acetylneuraminic acid synthetase activity enhanced by recombinant DNA techniques. Examples of such transformants include microorganisms carrying a recombinant DNA comprising neuB gene derived from Escherichia coli [J. Bacteriol., 171, 312 (1995)], specifically, Escherichia coli NM522/pYP18.

[0023] Any microorganism capable of producing pyruvic acid can be used in the process of the present invention. 20 Examples of suitable microorganisms are those of the species Escherichia coli, Corynebacterium ammoniagenes, Corynebacterium glutamicum, Corynebacterium acetoacidophilum and Saccharomyces cerevisiae. Also useful are microorganisms with pyruvic acid productivity enhanced by mutagenesis or recombinant DNA techniques. For example, the Escherichia coli mutant described in Biosci. Biotech. Biochem., 58, 2164 (1994) can be used.

[0024] Any microorganism capable of producing phosphoenolpyruvic acid can be used in the process of the present invention. Examples of suitable microorganisms are those of the species Escherichia coli, Corynebacterium ammoniagenes, Corynebacterium glutamicum, Corynebacterium acetoacidophilum and Saccharomyces cerevisiae. An example of the microorganism of the species Saccharomyces cerevisiae is the strain described in Japanese Published Unexamined Patent Application No. 197778/94. Also useful are microorganisms with phosphoenolpyruvic acid productivity enhanced by mutagenesis or recombinant DNA techniques.

30 [0025] Any microorganism having N-acetylglucosamine 2-epimerase activity can be used in the process of the present invention. Suitable microorganisms include transformants with N-acetylglucosamine 2-epimerase activity enhanced by recombinant DNA techniques. Specific examples of such transformants are Escherichia coli carrying the recombinant DNA pEPI1 comprising the N-acetylglucosamine 2-epimerase gene derived from pig (FERM BP-4602: U.S. Patent No. 5,795,767) and Escherichia coli NM522/pYP16 carrying a recombinant DNA comprising the N-acetylglucosamine 2-epimerase gene derived from a microorganism belonging to the genus Synechocystis.

35 [0026] An example of the N-acetylglucosamine 2-epimerase gene derived from a microorganism belonging to the genus Synechocystis is the gene encoding a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 which exists on the chromosome of Synechocystis sp. PCC6803, more specifically, the gene having the nucleotide sequence shown in SEQ ID NO: 2 (slr1975). The polypeptide having the amino acid sequence shown in SEQ ID NO: 1 and the DNA having the nucleotide sequence shown in SEQ ID NO: 2 have been obtained for the first time by the 40 present inventors according to the procedure described later in an example.

[0027] A microorganism having N-acetylneuraminic acid aldolase activity and the ability to produce pyruvic acid can be used alone for the production of N-acetylneuraminic acid from N-acetylmannosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement such property for producing N-acetylneuraminic acid.

45 [0028] N-Acetylmannosamine useful in the production of N-acetylneuraminic acid includes N - acetylmannosamine preparations (e.g., commercial products) and N-acetylmannosamine prepared from N-acetylglucosamine by chemical reaction under alkaline conditions or by enzymatic conversion using N-acetylglucosamine 2-epimerase. Also useful are preparations containing N-acetylmannosamine formed and accumulated by allowing a culture of a microorganism having N-acetylglucosamine 2-epimerase activity or a treated matter of the culture and N-acetylglucosamine to be present in an aqueous medium, and N-acetylmannosamine purified from such preparations.

50 [0029] A microorganism having N-acetylneuraminic acid aldolase activity, N-acetylglucosamine 2-epimerase activity and the ability to produce pyruvic acid can be used alone for the production of N-acetylneuraminic acid from N-acetylglucosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement such property for producing N-acetylneuraminic acid.

55 [0030] N-Acetylglucosamine useful in the production of N-acetylneuraminic acid includes N-acetylglucosamine preparations (e.g., commercial products).

[0031] A microorganism having N-acetylneuraminic acid synthetase activity and the ability to produce phosphoenolpyruvic acid can also be used alone for the production of N-acetylneuraminic acid from N-acetylmannosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement such property for producing N-acetylneuraminic acid.

5 [0032] Further, a microorganism having N-acetylneuraminic acid synthetase activity, N-acetylglucosamine 2-epimerase activity and the ability to produce phosphoenolpyruvic acid can be used alone for the production of N-acetylneuraminic acid from N-acetylglucosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement such property for producing N-acetylneuraminic acid.

10 [0033] The microorganisms employed in the production of N-acetylneuraminic acid or N-acetylmannosamine may be subjected to reaction to form the product during their growth stage. Alternatively, after the completion of culturing of a microorganism, the resulting culture or a treated matter of the culture may be subjected to reaction.

[0034] As described above, microorganisms prepared by using recombinant DNA techniques can be used in the production of N-acetylneuraminic acid or N-acetylmannosamine. Gene manipulating operations such as isolation and purification of plasmid DNA comprising a desired gene from a microorganism carrying the plasmid, cleavage of plasmid DNA with restriction enzymes, isolation and purification of cleaved DNA fragments, enzymatic ligation of DNA fragments, and transformation with recombinant DNA can be carried out according to known methods [e.g., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter referred to as Molecular Cloning, Second Edition); Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997) (hereinafter referred to as Current Protocols in Molecular Biology)]. Polymerase chain reaction (hereinafter referred to as PCR) can be carried out by a known method (PCR Protocols, Academic Press (1990)).

[0035] A gene concerned in the production of N-acetylneuraminic acid or N-acetylmannosamine can be expressed in a host by preparing a DNA fragment of an appropriate length containing the gene from a DNA fragment containing the gene by use of restriction enzymes or PCR, inserting the prepared DNA fragment into an appropriate expression vector at a site downstream of the promoter, and then introducing the expression vector comprising the above DNA into a host cell suited for the expression vector.

25 [0036] As the host cell, any bacterial cells, yeast cells, etc. which are capable of expressing a desired gene can be used.

[0037] The expression vectors that can be employed are those capable of autonomous replication or integration into chromosome in the above host cells and comprising a promoter at a position appropriate for the transcription of a desired DNA.

[0038] When a procaryotic cell such as a bacterial cell is used as the host cell, it is preferred that the expression vector for a gene is a recombinant DNA which is capable of autonomous replication in the procaryotic cell and which comprises a promoter, a ribosome binding sequence, the desired DNA, and a transcription termination sequence. The vector may further comprise a gene regulating the promoter.

35 [0039] Examples of suitable expression vectors are pBTrp2 (Roche Diagnostics), pBTac1 (Roche Diagnostics), pBTac2 (Roche Diagnostics), pHelix1 (Roche Diagnostics), pKK233-2 (Amersham Pharmacia Biotech), pKK223-3 (Amersham Pharmacia Biotech), pGEX-2T (Amersham Pharmacia Biotech), pSE280 (Invitrogen), pGEMEX-1 (Promega), pQE-8 (QIAGEN), pQE-30 (QIAGEN), pET-3 (Novagen), pKYP10 (Japanese Published Unexamined Patent Application No. 110600/83), pKYP200 [Agric. Biol. Chem., 48, 669 (1984)], pLSA1 (Agric. Biol. Chem., 53, 277 (1989)), pGEL1 (Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)), pBluescript II SK+ (Stratagene), pBluescript II SK-(Stratagene), pTrs30 [prepared from *Escherichia coli* JM109/pTrs30 (FERM BP-5407)], pTrs32 [prepared from *Escherichia coli* JM109/pTrs32 (FERM BP-5408)], pUC19 [Gene, 33, 103 (1985)], pSTV28 (Takara Shuzo Co., Ltd.), pUC118 (Takara Shuzo Co., Ltd.), pPAC31 (WO 98/12343) and pPA1 (Japanese Published Unexamined Patent Application No. 233798/88).

45 [0040] As the promoter, any promoters capable of functioning in host cells such as *Escherichia coli* can be used. For example, promoters derived from *Escherichia coli* or phage, such as *trp* promoter (P_{trp}), *lac* promoter (P_{lac}), P_L promoter, P_R promoter and P_{SE} promoter. SPO1 promoter, SPO2 promoter and penP promoter can be used. Artificially modified promoters such as a promoter in which two P_{trp} are combined in tandem, *tac* promoter, *lac*T7 promoter and *letI* promoter, etc. can also be used.

[0041] It is preferred to use a plasmid in which the distance between the Shine-Dalgarno sequence (ribosome binding sequence) and the initiation codon is adjusted to an appropriate length (e.g., 6-18 bases).

[0042] In the recombinant DNA of the present invention, the transcription termination sequence is not essential for the expression of the desired DNA, but it is preferred that the transcription termination sequence lie immediately downstream of the structural gene.

55 [0043] Examples of suitable procaryotes are microorganisms belonging to the genera *Escherichia*, *Serratia*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Microbacterium* and *Pseudomonas*, specifically, *Escherichia coli* XL1-Blue, *Escherichia coli* XL2-Blue, *Escherichia coli* DH1, *Escherichia coli* MC1000, *Escherichia coli* W1485, *Escherichia coli*

NM522, Escherichia coli JM109, Escherichia coli HB101, Escherichia coli No. 49, Escherichia coli W3110, Escherichia coli NY49, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Bacillus subtilis, Bacillus amyloliquefaciens, Brevibacterium immariophilum ATCC 14068, Brevibacterium saccharolyticum ATCC 14066, Corynebacterium ammoniagenes, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 14067, Corynebacterium glutamicum ATCC 13869, Corynebacterium acetoacidophilum ATCC 13870, Microbacterium ammoniaphilum ATCC 15354 and Pseudomonas sp. D-0110.

[0044] Introduction of the recombinant DNA can be carried out by any of the methods for introducing DNA into the above host cells, for example, the method using calcium ion [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], the protoplast method (Japanese Published Unexamined Patent Application No. 248394/88) and electroporation [Nucleic Acids Research, 16, 6127 (1988)].

[0045] When a yeast cell is used as the host cell, YEp13 (ATCC 37115), YEp24 (ATCC 37051), YCp50 (ATCC 37419), pHS19, pHS15, etc. can be used as the expression vector.

[0046] As the promoter, any promoters capable of functioning in yeast cells can be used. Suitable promoters include PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock polypeptide promoter, MF α 1 promoter, CUP 1 promoter, etc.

[0047] Examples of suitable host cells are cells of yeast strains belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwanniomyces, Pichia and Candida, specifically, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans, Schwanniomyces alluvius, Pichia pastoris and Candida utilis.

[0048] Introduction of the recombinant DNA can be carried out by any of the methods for introducing DNA into yeast cells, for example, electroporation [Methods in Enzymol., 194, 182 (1990)], the spheroplast method (Proc. Natl. Acad. Sci. USA, 81, 4889 (1984)] and the lithium acetate method (J. Bacteriol., 153, 163 (1983)).

[0049] Culturing of the transformant of the present invention can be carried out by conventional methods for culturing the host cell of the transformant.

[0050] For the culturing of the transformant prepared by using a procaryotic cell such as Escherichia coli cell or a eucaryotic cell such as a yeast cell as the host cell, any of natural media and synthetic media can be used insofar as it is a medium suitable for efficient culturing of the transformant which contains carbon sources, nitrogen sources, inorganic substances, etc. which can be assimilated by the host used.

[0051] As the carbon sources, any carbon sources which can be assimilated by the host can be used. Examples of suitable carbon sources include carbohydrates such as glucose, fructose, sucrose, molasses containing them, starch and starch hydrolyzate; organic acids such as acetic acid and propionic acid; and alcohols such as ethanol and propanol.

[0052] As the nitrogen sources, ammonia, ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate and ammonium phosphate, and other nitrogen-containing compounds can be used as well as peptone, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, soybean cake, soybean cake hydrolyzate, and various fermented cells and digested products thereof.

[0053] Examples of the inorganic substances include potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate and calcium carbonate.

[0054] Culturing is usually carried out under aerobic conditions, for example, by shaking culture or submerged spinner culture under aeration, at 15-40°C for 5 hours to 7 days. The pH is maintained at 3.0-9.0 during the culturing. The pH adjustment is carried out by using an inorganic or organic acid, an alkali solution, urea, calcium carbonate, ammonia, etc.

[0055] If necessary, antibiotics such as ampicillin and tetracycline may be added to the medium during the culturing.

[0056] When a microorganism transformed with an expression vector comprising an inducible promoter is cultured, an inducer may be added to the medium, if necessary. For example, in the case of a microorganism transformed with an expression vector comprising lac promoter, isopropyl- β -D-thiogalactopyranoside or the like may be added to the medium; and in the case of a microorganism transformed with an expression vector comprising trp promoter, indoleacrylic acid or the like may be added.

[0057] The treated matters of a culture include concentrated culture, dried culture, cells obtained by centrifuging the culture, products obtained by treating the cells by various means such as drying, freeze-drying, treatment with a surfactant, ultrasonication, mechanical friction, treatment with a solvent, enzymatic treatment, protein fractionation and immobilization, an enzyme preparation obtained by extracting the cells, etc.

[0058] The amount of each microorganism used in the production of N-acetylneuraminic acid or N-acetylmannosamine is 1-500 g/l, preferably 1-300 g/l, as wet cells.

[0059] As the energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid, any substance can be used that promotes the formation of pyruvic acid or phosphoenolpyruvic acid. Examples of preferred

substances are glucose and fructose. The substances may be used usually at a concentration of 10-300 g/l.

[0060] Aqueous media useful in the production of N-acetylneuraminic acid or N-acetylmannosamine include water, buffers such as phosphate buffer, carbonate buffer, acetate buffer, borate buffer, citrate buffer and Tris buffer, alcohols such as methanol and ethanol, esters such as ethyl acetate, ketones such as acetone, amides such as acetamide, etc. Also useful is a medium or culture broth of a microorganism used in the process for producing N-acetylneuraminic acid or N-acetylmannosamine.

[0061] If necessary, a chelating agent (e.g., phytic acid), a surfactant or an organic solvent may be added in the process for producing N-acetylneuraminic acid or N-acetylmannosamine.

[0062] Any surfactant that promotes the formation of N-acetylneuraminic acid or N-acetylmannosamine can be used. Suitable surfactants include nonionic surfactants such as polyoxyethylene octadecylamine (e.g., Nymeen S-215, NOF Corporation), cationic surfactants such as cetyltrimethylammonium bromide and alkyldimethyl benzylammonium chloride (e.g., Cation F2 - 40E, NOF Corporation), anionic surfactants such as lauroyl sarcosinate, and tertiary amines such as alkyldimethylamine (e.g., Tertiary Amine FB, NOF Corporation), which may be used alone or in combination. The surfactant is usually used at a concentration of 0.1-50 g/l.

[0063] As the organic solvent, xylene, toluene, aliphatic alcohols, acetone, ethyl acetate, etc. may be used usually at a concentration of 0.1-50 ml/l.

[0064] The reaction for forming N-acetylneuraminic acid or N-acetylmannosamine is carried out in an aqueous medium at pH 5-10, preferably pH 6-8, at 20-50°C for 1-96 hours.

[0065] Adenine, adenosine 5'-monotriphosphate (AMP), adenosine 5'-triphosphate (ATP), magnesium sulfate, magnesium chloride, etc. may be added for promoting the reaction. Adenine, AMP and ATP are usually used at a concentration of 0.01-100 mmol/l.

[0066] N-Acetylneuraminic acid or N-acetylmannosamine formed in the aqueous medium can be determined by using a carbohydrate analysis system (Dionex) or the like [Anal. Biochem., 189, 151 (1990)].

[0067] N-Acetylneuraminic acid or N-acetylmannosamine can be recovered from the reaction mixture by ordinary methods using active carbon, ion-exchange resins, etc.

[0068] Certain embodiments of the present invention are illustrated in the following examples. These examples are not to be construed as limiting the scope of the invention.

Example 1

Construction of a Strain Expressing N-Acetylneuraminic Acid Aldolase Gene Derived from *Escherichia coli*

[0069] *Escherichia coli* W3110 (ATCC 27325) was cultured by the method described in Current Protocols in Molecular Biology and the chromosomal DNA of the microorganism was isolated and purified.

[0070] The DNA primer shown in SEQ ID NO: 3 and the DNA primer shown in SEQ ID NO: 4 were synthesized by using a DNA synthesizer (Model 8905, PerSeptive Biosystems).

[0071] PCR was carried out using the above synthetic DNAs as primers and the chromosomal DNA of *Escherichia coli* W3110 (ATCC 27325) as a template. That is, PCR was carried out by 30 cycles, one cycle consisting of reaction at 94°C for one minute, reaction at 42°C for 2 minutes and reaction at 72°C for 3 minutes, using 40 µl of a reaction mixture comprising 0.1 µg of the chromosomal DNA, 0.5 µmol/l each of the primers, 2.5 units of Pfu DNA polymerase (Stratagene), 4 µl of buffer for Pfu DNA polymerase (10 x) (Stratagene) and 200 µmol/l each of deoxyNTPs.

[0072] One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE [10 mmol/l Tris-HCl (pH 8.0), 1 mmol/l EDTA], followed by centrifugation. The obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80°C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.

[0073] The DNA precipitate was dissolved in 20 µl of TE and 5 µl of the solution was subjected to reaction to cleave the DNA with restriction enzymes *Hind*III and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 1.2 kb fragment was recovered using Gene Clean II Kit (Bio 101). pUC19 DNA [Gene, 33, 103 (1985)] (0.2 µg) was cleaved with restriction enzymes *Hind*III and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 2.7 kb fragment was recovered in the same manner.

[0074] The 1.2 kb fragment and 2.7 kb fragment obtained above were subjected to ligation reaction using a ligation kit at 16°C for 16 hours. *Escherichia coli* NM522 capable of producing pyruvic acid was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50 µg/ml ampicillin, and cultured overnight at 30°C.

[0075] *Escherichia coli* NM522/pTA3, which is a transformant carrying the N-acetylneuraminic acid aldolase gene, *nanA*, was obtained from a colony of the transformant that grew on the above medium. A plasmid was extracted from this transformant by a known method to obtain pTA3, which is a plasmid for expression of N-acetylneuraminic acid aldo-

EP 1 081 230 A2

lase gene. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 1).

Example 2

5 Production of N-Acetylneuraminic Acid

[0076] *Escherichia coli* NM522/pTA3 obtained in Example 1 was inoculated into 125 ml of LB medium containing 50 µg/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed by culturing at 28° C with stirring (220 r.p.m.) for 17 hours. The resulting culture (125 ml) was inoculated into 2.5 l of a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l KH₂PO₄, 12.5 g/l K₂HPO₄ and 50 µg/ml ampicillin in a 5-l jar fermentor. Culturing was carried out at 37° C for 6 hours under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing. The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0077] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pTA3 wet cells, 65 g/l fructose, 40 g/l N-acetylmannosamine, 25 g/l KH₂PO₄, 5 g/l MgSO₄ · 7H₂O, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 25 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH₂PO₄ were added to the reaction mixture.

[0078] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 0.34 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

25 Example 3

Construction of a Strain Expressing N-Acetylneuraminic acid synthetase Gene Derived from *Escherichia coli*

[0079] *Escherichia coli* K235 (ATCC 13027) was cultured by the method described in Current Protocols in Molecular Biology and the chromosomal DNA of the microorganism was isolated and purified.

[0080] The DNA primer shown in SEQ ID NO: 5 and the DNA primer shown in SEQ ID NO: 6 were synthesized by using a DNA synthesizer (Model 8905, PerSeptive Biosystems).

[0081] PCR was carried out using the above synthetic DNAs as primers and the chromosomal DNA of *Escherichia coli* K235 (ATCC 13027) as a template. That is, PCR was carried out by 30 cycles, one cycle consisting of reaction at 94° C for one minute, reaction at 42° C for 2 minutes and reaction at 72° C for 3 minutes, using 40 µl of a reaction mixture comprising 0.1 µg of the chromosomal DNA, 0.5 µmol/l each of the primers, 2.5 units of Pfu DNA polymerase (Stratagene), 4 µl of buffer for Pfu DNA polymerase (10 x) (Stratagene) and 200 µmol/l each of deoxyNTPs.

[0082] One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE, followed by centrifugation. The obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80° C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.

[0083] The DNA precipitate was dissolved in 20 µl of TE and 5 µl of the solution was subjected to reaction to cleave the DNA with restriction enzymes *Cla*I and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 1.1 kb fragment was recovered using Gene Clean II Kit (Bio 101). pPAC31 DNA (WO98/12343) (0.2 µg) was cleaved with restriction enzymes *Cla*I and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 5.5 kb fragment was recovered in the same manner.

[0084] The 1.1 kb fragment and 5.5 kb fragment obtained above were subjected to ligation reaction using a ligation kit at 16° C for 16 hours. *Escherichia coli* NM522 capable of producing phosphoenolpyruvic acid was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50 µg/ml ampicillin, and cultured overnight at 30° C.

[0085] *Escherichia coli* NM522/pYP18, which is a transformant carrying the N-acetylneuraminic acid synthetase gene, *neuB*, was obtained from a colony of the transformant that grew on the above medium. A plasmid was extracted from this transformant by a known method to obtain pYP18, which is a plasmid for expression of N-acetylneuraminic acid synthetase gene. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 2).

Example 4

Production of N-Acetylneuraminic Acid

5 [0086] *Escherichia coli* NM522/pYP18 obtained in Example 3 was inoculated into 125 ml of LB medium containing 50 µg/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed by culturing at 28° C with stirring (220 r.p.m.) for 17 hours. The resulting culture (125 ml) was inoculated into 2.5 l of a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l KH₂PO₄, 12.5 g/l K₂HPO₄ and 50 µg/ml ampicillin in a 5-l jar fermentor. Culturing was carried out at 37° C for 4 hours and then at 40°

10 C for 3 hours, under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing.

[0087] The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

15 [0088] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pYP18 wet cells, 65 g/l fructose, 40 g/l N-acetylmannosamine, 25 g/l KH₂PO₄, 5 g/l MgSO₄ · 7H₂O, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 19 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH₂PO₄ were added to the reaction mixture.

20 [0089] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.4 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

Example 5

25

Production of N-Acetylneuraminic Acid

[0090] *Escherichia coli* NM522/pYP18 obtained in Example 3 was cultured according to the method described in Example 2 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and

30 could be used after thawing, according to need.

[0091] *Corynebacterium ammoniagenes* ATCC 21170 was inoculated into 25 ml of a liquid medium comprising 50 g/l glucose, 10 g/l polypeptone (Nihon Pharmaceutical Industrial Co., Ltd.), 10 g/l yeast extract (Oriental Yeast Co., Ltd.), 5 g/l urea, 5 g/l (NH₄)₂SO₄, 1 g/l KH₂PO₄, 3 g/l K₂HPO₄, 1 g/l MgSO₄ · 7H₂O, 0.1 g/l CaCl₂ · 2H₂O, 10 mg/l FeSO₄ · 7H₂O, 10 mg/l ZnSO₄ · 7H₂O, 20 mg/l MnSO₄ · 4-6H₂O, 20 mg/l L-cysteine, 10 mg/l calcium D-pantothenate, 5 mg/l vitamin B₁, 5 mg/l nicotinic acid and 30 µg/l biotin (adjusted to pH 7.2 with 10 N NaOH) in a 300-ml Erlenmeyer flask with baffles, followed by culturing at 28° C with stirring (220 r.p.m.) for 24 hours.

35

[0092] The resulting culture (20 ml) was inoculated into 250 ml of a liquid medium having the same composition as above in a 2-l Erlenmeyer flask with baffles, followed by culturing at 28° C with stirring (220 r.p.m.) for 24 hours. The obtained culture was used as a seed culture.

40 [0093] The seed culture (250 ml) was inoculated into 2.25 l of a liquid medium comprising 150 g/l glucose, 5 g/l meat extract (Kyokuto Pharmaceutical Ind. Co., Ltd.), 10 g/l KH₂PO₄, 10 g/l K₂HPO₄, 10 g/l MgSO₄ · 7H₂O, 0.1 g/l CaCl₂ · 2H₂O, 20 mg/l FeSO₄ · 7H₂O, 10 mg/l ZnSO₄ · 7H₂O, 20 mg/l MnSO₄ · 4-6H₂O (separately sterilized), 15 mg/l β-alanine (separately sterilized), 20 mg/l L-cysteine, 100 µg/l biotin, 2 g/l urea and 5 mg/l vitamin B₁ (separately sterilized) (adjusted to pH 7.2 with 10 N NaOH) in a 5-l jar fermentor. Culturing was carried out at 32° C for 24 hours

45 under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 6.8 with 28% aqueous ammonia.

[0094] The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

50 [0095] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pYP18 wet cells, 150 g/l *Corynebacterium ammoniagenes* ATCC 21170 wet cells, 65 g/l fructose, 40 g/l N-acetylmannosamine, 25 g/l KH₂PO₄, 5 g/l MgSO₄ · 7H₂O, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 6 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH₂PO₄ were added to the reaction mixture.

55 [0096] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 3.1 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

Example 6Construction of a Strain Expressing N-Acetylglucosamine 2-Epimerase Gene Derived from *Synechocystis*

- 5 [0097] Blast Search of Genbank and a similarity search on CyanoBase (<http://www.kazusa.or.jp/cyano/>), which is a database of the genomic sequence of *Synechocystis* sp. (PCC6803), were conducted with the amino acid sequence of N-acetylglucosamine 2-epimerase derived from pig [J. Biol. Chem., 271, 16294 (1996)] as a query. As a result, the above amino acid sequence showed a high homology to the sequence derived from *Synechocystis* sp. (PCC6803) described as a renin-binding protein (slr1975).
- 10 [0098] *Synechocystis* sp. (PCC6803) was cultured by the method described in J. Gen. Microbiol., 111, 1 (1979), and the chromosomal DNA of the microorganism was isolated and purified by the method described in Current Protocols in Molecular Biology.
- [0099] PCR was carried out according to the method described in Example 1 using the DNAs shown in SEQ ID NOS: 7 and 8 which had been synthesized by using a DNA synthesizer (Model 8905, PerSeptive Biosystems) as primers and the chromosomal DNA of *Synechocystis* sp. (PCC6803) as a template.
- 15 [0100] One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE.
- [0101] The resulting mixture was centrifuged and the obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80° C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.
- 20 [0102] The DNA precipitate was dissolved in 20 µl of TE and 5 µl of the solution was subjected to reaction to cleave the DNA with restriction enzymes *Cla*I and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 1.2 kb fragment was recovered using Gene Clean II Kit (Bio 101).
- 25 [0103] pPAC31 DNA (0.2 µg) was cleaved with restriction enzymes *Cla*I and *Bam*HI. DNA fragments were separated by agarose gel electrophoresis and a 5.5 kb fragment was recovered in the same manner.
- [0104] The 1.2 kb fragment and 5.5 kb fragment obtained above were subjected to ligation reaction using a ligation kit at 16° C for 16 hours.
- [0105] *Escherichia coli* NM522 was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50 µg/ml ampicillin, and cultured overnight at 30° C.
- 30 [0106] *Escherichia coli* NM522/pYP16, which is a transformant carrying the DNA encoding N-acetylglucosamine 2-epimerase derived from *Synechocystis* sp., was obtained from a colony of the transformant that grew on the above medium. A plasmid was extracted from this transformant by a known method to obtain expression plasmid pYP16. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 3).

Example 7

Production of N-Acetylneuraminic Acid

- 40 [0107] *Escherichia coli* NM522/pTA3 obtained in Example 1 was cultured according to the method described in Example 2 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.
- [0108] *Escherichia coli* NM522/pYP16 obtained in Example 6 was inoculated into 125 ml of LB medium containing 50 µg/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed by culturing at 28° C with stirring (220 r.p.m.) for 17
- 45 hours. The resulting culture (125 ml) was inoculated into 2.5 l of a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l KH₂PO₄, 12.5 g/l K₂HPO₄ and 50 µg/ml ampicillin in a 5-l jar fermentor. Culturing was carried out at 30° C for 4 hours and then at 40° C for 3 hours, under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing.
- 50 [0109] The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.
- [0110] *Corynebacterium ammoniagenes* ATCC 21170 was cultured according to the method described in Example 5 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.
- 55 [0111] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pTA3 wet cells, 50 g/l *Escherichia coli* NM522/pYP16 wet cells, 150 g/l *Corynebacterium ammoniagenes* ATCC 21170 wet cells, 65 g/l fructose, 180 g/l N-acetylglucosamine, 25 g/l KH₂PO₄, 5 g/l MgSO₄ · 7H₂O, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was

EP 1 081 230 A2

put into a 200-ml beaker and subjected to reaction at 32° C for 24 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH_2PO_4 were added to the reaction mixture.

[0112] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.0 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

Example 8

10 Production of N-Acetylneuraminic Acid

[0113] *Escherichia coli* NM522/pYP18 obtained in Example 3 and *Escherichia coli* NM522/pYP16 obtained in Example 6 were cultured according to the methods described in Examples 4 and 7, respectively, and the resulting cultures were centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0114] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pYP16 wet cells, 50 g/l *Escherichia coli* NM522/pYP18 wet cells, 65 g/l fructose, 180 g/l N-acetylglucosamine, 25 g/l KH_2PO_4 , 5 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 11 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH_2PO_4 were added to the reaction mixture.

[0115] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.3 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

25 Example 9

Production of N-Acetylneuraminic Acid

[0116] *Escherichia coli* NM522/pYP18 obtained in Example 3 and *Escherichia coli* NM522/pYP16 obtained in Example 6 were cultured according to the methods described in Examples 4 and 7, respectively, and the resulting cultures were centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0117] *Corynebacterium ammoniagenes* ATCC 21170 was cultured according to the method described in Example 5 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0118] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pYP16 wet cells, 50 g/l *Escherichia coli* NM522/pYP18 wet cells, 150 g/l *Corynebacterium ammoniagenes* ATCC 21170 wet cells, 65 g/l fructose, 180 g/l N-acetylglucosamine, 25 g/l KH_2PO_4 , 5 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 24 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and KH_2PO_4 were added to the reaction mixture.

[0119] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 4.3 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

45 Example 10

Production of N-Acetylneuraminic Acid

[0120] *Escherichia coli* NM522/pYP18 obtained in Example 3 and *Escherichia coli* NM522/pYP16 obtained in Example 6 were cultured according to the methods described in Examples 4 and 7, respectively, and the resulting cultures were centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0121] *Corynebacterium ammoniagenes* ATCC 21170 was cultured according to the method described in Example 5 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20° C and could be used after thawing, according to need.

[0122] A reaction mixture (30 ml) comprising 50 g/l *Escherichia coli* NM522/pYP16 wet cells, 50 g/l *Escherichia coli* NM522/pYP18 wet cells, 150 g/l *Corynebacterium ammoniagenes* ATCC 21170 wet cells, 100 g/l glucose, 180 g/l N-

EP 1 081 230 A2

acetylglucosamine, 5 g/l adenine, 15 g/l KH_2PO_4 , 5 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 22 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, glucose and KH_2PO_4 were added to the reaction mixture.

5 [0123] After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 12.3 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> KYOWA HAKKO KOGYO CO., LTD.

<120> Process for producing N-acetylneuraminic acid

10 <130> 11229

<150> H11-242670

15 <151> 1999-08-30

<160> 8

20 <170> PatentIn Ver. 2.0

<210> 1

25 <211> 391

<212> PRT

<213> Synechocystis sp. (PCC6803)

30 <400> 1

Met Ile Ala His Arg Arg Gln Glu Leu Ala Gln Gln Tyr Tyr Gln Ala

1 5 10 15

35 Leu His Gln Asp Val Leu Pro Phe Trp Glu Lys Tyr Ser Leu Asp Arg

20 25 30

40 Gln Gly Gly Gly Tyr Phe Thr Cys Leu Asp Arg Lys Gly Gln Val Phe

35 40 45

45 Asp Thr Asp Lys Phe Ile Trp Leu Gln Asn Arg Gln Val Trp Gln Phe

50 55 60

50 Ala Val Phe Tyr Asn Arg Leu Glu Pro Lys Pro Gln Trp Leu Glu Ile

65 70 75 80

55

EP 1 081 230 A2

Ala Arg His Gly Ala Asp Phe Leu Ala Arg His Gly Arg Asp Gln Asp
85 90 95

Gly Asn Trp Tyr Phe Ala Leu Asp Gln Glu Gly Lys Pro Leu Arg Gln
100 105 110

Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln
115 120 125

Tyr Ala Leu Ala Ser Gly Ala Gln Glu Ala Lys Ala Ile Ala Leu Gln
130 135 140

Ala Tyr Asn Asn Val Leu Arg Arg Gln His Asn Pro Lys Gly Gln Tyr
145 150 155 160

Glu Lys Ser Tyr Pro Gly Thr Arg Pro Leu Lys Ser Leu Ala Val Pro
165 170 175

Met Ile Leu Ala Asn Leu Thr Leu Glu Met Glu Trp Leu Leu Pro Pro
180 185 190

Thr Thr Val Glu Glu Val Leu Ala Gln Thr Val Arg Glu Val Met Thr
195 200 205

Asp Phe Leu Asp Pro Glu Ile Gly Leu Met Arg Glu Ala Val Thr Pro
210 215 220

Thr Gly Glu Phe Val Asp Ser Phe Glu Gly Arg Leu Leu Asn Pro Gly
225 230 235 240

His Gly Ile Glu Ala Met Trp Phe Met Met Asp Ile Ala Gln Arg Ser
245 250 255

Gly Asp Arg Gln Leu Gln Glu Gln Ala Ile Ala Val Val Leu Asn Thr
260 265 270

EP 1 081 230 A2

5 Leu Glu Tyr Ala Trp Asp Glu Glu Phe Gly Gly Ile Phe Tyr Phe Leu
 275 280 285
 Asp Arg Gln Gly His Pro Pro Gln Gln Leu Glu Trp Asp Gln Lys Leu
 290 295 300
 10 Trp Trp Val His Leu Glu Thr Leu Val Ala Leu Ala Lys Gly His Gln
 305 310 315 320
 15 Ala Thr Gly Gln Glu Lys Cys Trp Gln Trp Phe Glu Arg Val His Asp
 325 330 335
 20 Tyr Ala Trp Ser His Phe Ala Asp Pro Glu Tyr Gly Glu Trp Phe Gly
 340 345 350
 25 Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys
 355 360 365
 30 Trp Lys Gly Cys Phe His Val Pro Arg Ala Leu Trp Leu Cys Ala Glu
 370 375 380
 35 Thr Leu Gln Leu Pro Val Ser
 385 390
 40 <210> 2
 <211> 1173
 <212> DNA
 <213> Synechocystis sp. (PCC6803)
 45 <400> 2
 atg att gcc cat cgc cgt cag gag tta gcc cag caa tat tac cag gct 48
 Met Ile Ala His Arg Arg Gln Glu Leu Ala Gln Gln Tyr Tyr Gln Ala
 1 5 10 15
 50 tta cac cag gac gla ttg ccc ttt tgg gaa aaa tat tcc ctc gat cgc 96
 55

EP 1 081 230 A2

	Leu His Gln Asp Val Leu Pro Phe Trp Glu Lys Tyr Ser Leu Asp Arg	
	20 25 30	
5		
	cag ggg ggc ggt tac ttt acc tgc tta gac cgt aaa ggc cag gtt ttt	144
	Gln Gly Gly Gly Tyr Phe Thr Cys Leu Asp Arg Lys Gly Gln Val Phe	
10	35 40 45	
	gac aca gat aaa ttc att tgg tta caa aac cgt cag gta tgg cag ttt	192
	Asp Thr Asp Lys Phe Ile Trp Leu Gln Asn Arg Gln Val Trp Gln Phe	
15	50 55 60	
	gcc gtt ttc tac aac cgt ttg gaa cca aaa ccc caa tgg tta gaa att	240
20	Ala Val Phe Tyr Asn Arg Leu Glu Pro Lys Pro Gln Trp Leu Glu Ile	
	65 70 75 80	
	gcc cgc cat ggt gct gat ttt tta gct cgc cac ggc cga gat caa gac	288
25	Ala Arg His Gly Ala Asp Phe Leu Ala Arg His Gly Arg Asp Gln Asp	
	85 90 95	
	ggt aat tgg tat ttt gct ttg gat cag gaa ggc aaa ccc ctg cgt caa	336
30	Gly Asn Trp Tyr Phe Ala Leu Asp Gln Glu Gly Lys Pro Leu Arg Gln	
	100 105 110	
	ccc tat aac gtt ttt tcc gat tgc ttc gcc gcc atg gcc ttt agt caa	384
35	Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln	
	115 120 125	
	tat gcc tta gcc agt ggg gcg cag gaa gct aaa gcc att gcc ctg cag	432
40	Tyr Ala Leu Ala Ser Gly Ala Gln Glu Ala Lys Ala Ile Ala Leu Gln	
	130 135 140	
	gcc tac aat aac gtc cta cgc cgt cag cac aat ccc aaa ggt caa tac	480
45	Ala Tyr Asn Asn Val Leu Arg Arg Gln His Asn Pro Lys Gly Gln Tyr	
	145 150 155 160	
50		
	gag aag tcc tat cca ggt act aga ccc ctc aaa tcc ctg gcg gtg ccg	528
55		

EP 1 081 230 A2

	Glu Lys Ser Tyr Pro Gly Thr Arg Pro Leu Lys Ser Leu Ala Val Pro	
	165 170 175	
5		
	atg att tta gcc aac ctc acc ctg gag atg gaa tgg tta tta ccg cct	576
	Met Ile Leu Ala Asn Leu Thr Leu Glu Met Glu Trp Leu Leu Pro Pro	
10	180 185 190	
	act acc gtg gaa gag gtg ttg gcc caa acc gtc aga gaa gtg atg acg	624
	Thr Thr Val Glu Glu Val Leu Ala Gln Thr Val Arg Glu Val Met Thr	
15	195 200 205	
	gat ttc ctc gac cca gaa ata gga tta atg cgg gaa gcg gtg acc ccc	672
	Asp Phe Leu Asp Pro Glu Ile Gly Leu Met Arg Glu Ala Val Thr Pro	
20	210 215 220	
	aca gga gaa ttt gtt gat agt ttt gaa ggg cgg ttg ctc aac cca gga	720
	Thr Gly Glu Phe Val Asp Ser Phe Glu Gly Arg Leu Leu Asn Pro Gly	
25	225 230 235 240	
	cac ggc att gaa gcc atg tgg ttc atg atg gac att gcc caa cgc tcc	768
	His Gly Ile Glu Ala Met Trp Phe Met Met Asp Ile Ala Gln Arg Ser	
30	245 250 255	
	ggc gat cgc cag tta cag gag caa gcc att gca glg gtg ttg aac acc	816
	Gly Asp Arg Gln Leu Gln Glu Gln Ala Ile Ala Val Val Leu Asn Thr	
35	260 265 270	
	ctg gaa tat gcc tgg gat gaa gaa ttt ggt ggc ata ttt tat ttc ctt	864
	Leu Glu Tyr Ala Trp Asp Glu Glu Phe Gly Gly Ile Phe Tyr Phe Leu	
40	275 280 285	
	gat cgc cag ggc cac cct ccc caa caa ctg gaa tgg gac caa aag ctc	912
	Asp Arg Gln Gly His Pro Pro Gln Gln Leu Glu Trp Asp Gln Lys Leu	
45	290 295 300	
	tgg tgg gta cat ttg gaa acc ctg gtt gcc cta gcc aag ggc cac caa	960
50		
55		

EP 1 081 230 A2

Trp Trp Val His Leu Glu Thr Leu Val Ala Leu Ala Lys Gly His Gln
 305 310 315 320

5

gcc act ggc caa gaa aaa tgt tgg caa tgg ttt gag cgg gtc cat gat 1008
 Ala Thr Gly Gln Glu Lys Cys Trp Gln Trp Phe Glu Arg Val His Asp
 10 325 330 335

tac gcc tgg agt cat ttc gcc gat cct gag tat ggg gaa tgg ttt ggc 1056
 Tyr Ala Trp Ser His Phe Ala Asp Pro Glu Tyr Gly Glu Trp Phe Gly
 15 340 345 350

tac ctg aat cgc cgg gga gag gtg tta ctc aac cta aaa ggg ggg aaa 1104
 Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys
 20 355 360 365

tgg aaa ggg tgc ttc cac gtg ccc cga gct ctg tgg ctc tgt gcg gaa 1152
 Trp Lys Gly Cys Phe His Val Pro Arg Ala Leu Trp Leu Cys Ala Glu
 25 370 375 380

act ctc caa ctt ccg gtt agt 1173
 Thr Leu Gln Leu Pro Val Ser
 30 385 390

35

<210> 3
 <211> 24
 40 <212> DNA
 <213> Artificial Sequence

<220>
 45 <223> Synthetic DNA

<400> 3
 50 ggttaagctt tctgtatggg gtgt
 24

55

EP 1 081 230 A2

5
10
15
20
25
30
35
40
45
50
55

<210> 4
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic DNA

<400> 4
gcagggatcc caaccaggca gcggaa
26

<210> 5
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic DNA

<400> 5
tttatcgata ttaattaggg ggaatgaatg ag
32

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic DNA

<400> 6

tttggatcct cattattccc cctgattttt gaa

33

<210> 7

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 7

taaatcgata ttigtatgat tgcccatcgc cgtcag

36

<210> 8

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 8

aaagatcct taactaaccg gaagttggag agtttc

36

Claims

1. A process for producing N-acetylneuraminic acid which comprises:

allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid aldolase activity is used in (i) above, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid synthetase activity is used in (i) above, (iii) N-acetylmannosamine, and (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and recovering N-acetylneuraminic acid from the aqueous medium.

EP 1 081 230 A2

2. The process according to claim 1, wherein said N-acetylmannosamine is produced by allowing a culture of a microorganism having N- acetylglucosamine 2 -epimerase activity or a treated matter of the culture and N-acetylglucosamine to be present in an aqueous medium to form and accumulate N-acetylmannosamine in the aqueous medium.
3. The process according to claim 2, wherein said microorganism having N-acetylglucosamine 2-epimerase activity carries a recombinant DNA composed of a DNA fragment comprising DNA encoding N-acetylglucosamine 2-epimerase and a vector.
4. The process according to claim 3, wherein said DNA encoding N-acetylglucosamine 2-epimerase is DNA derived from a microorganism belonging to the genus Synechocystis.
5. The process according to claim 3 or 4, wherein said DNA encoding N-acetylglucosamine 2-epimerase is selected from the group consisting of:
- (a) DNA encoding a protein having the amino acid sequence shown in SEQ ID NO: 1; and
(b) DNA having the nucleotide sequence shown in SEQ ID NO: 2.
6. The process according to any of claims 1-5, wherein said microorganism having N-acetylneuraminic acid aldolase activity is a microorganism belonging to the genus Escherichia or Corynebacterium.
7. The process according to any of claims 1-6, wherein said microorganism having N-acetylneuraminic acid synthetase activity is a microorganism belonging to a genus selected from the group consisting of Escherichia, Neisseria and Streptococcus.
8. The process according to any of claims 1-7, wherein said microorganism capable of producing pyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.
9. The process according to any of claims 1-8, wherein said microorganism capable of producing phosphoenolpyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.
10. The process according to any of claims 6-9, wherein said microorganism belonging to the genus Escherichia is Escherichia coli.
11. The process according to claim 6, 8 or 9, wherein said microorganism belonging to the genus Corynebacterium is Corynebacterium ammoniagenes, Corynebacterium glutamicum or Corynebacterium acetoacidophilum.

Fig. 1




Fig. 2




Fig. 3

